Posts

Replimune Melanoma Drug Snags Coveted FDA Approval After Yearlong Clash, Two Rejections

on

Greg Verdine's LifeMine raises $263M for safer immunosuppressant

on

Braveheart lands ~$383M IPO to take Hengrui cardio drug into Phase 3

on

Takeda Orzeyful ile ilk kez narkolepsi tip 1'in tüm belirtilerini kapsayan bir tedavi aldı.

on

Moderna's mRNA flu shot mFlusiva wins FDA nod after refusal‑to‑file controversy

on

Recent acquisitions of digestive health startups: Hinge Health, P&G, and others

on

AI-Designed First‑In‑Class Small Molecule Inhibitor Shows Promise Against Pancreatic Cancer in Preclinical Studies

on

Merger talks between AstraZeneca and Bristol Myers Squibb are off, report says

on

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

on

Sanofi-backed Expedition raises $115M Series B to advance COPD drug EXPD-101 into Phase 2

on

Gilead's HIV PrEP Franchise Hits $1B+ Quarterly Sales, With Yeztugo Growth Tempered by Durability Concerns

on

Attovia CEO Fu plans muscle in on itch market with $289M IPO to challenge Dupixent

on

Novo CEO accepts R&D setbacks as CagriSema posts more mixed data and Novo eyes M&A

on